Ординатура / Офтальмология / Английские материалы / Primary Intraocular Lymphoma_Chan, Gonzales_2007
.pdf
Table 10.1 (Continued)
Patient Characteristics |
|
|
|
Treatment Regimen |
N |
Outcome |
Author |
|
|
|
|
21 PIOL/PCNSL pts |
|
2-year OS 39 +/− 11% |
Ferreri, et. al.53 |
1 PIOL pt |
|
|
|
Chemo OWBRT |
8 |
OS of 47+ months |
|
Chemo WBRT or no OWBRT |
10b |
OS of 9.5+ months |
|
RT |
3 |
OS of 10 months |
|
No Tx |
1 |
— |
|
|
|
|
|
PIOL/PCNSL |
7 |
|
Batchelor, et. al.39 |
PIOL |
2 |
|
|
Induction |
|
|
|
8 g/m2 IV-MTX q14 days until complete response |
|
|
|
Consolidation |
|
|
|
8 g/m2 IV-MTX q14 days X 2 doses |
|
|
|
Maintenance |
|
|
|
8 g/m2 IV-MTX q28 days X 11 doses |
|
|
|
|
|
Micromolar concentrations of MTX present in both ocular |
|
|
|
chambers 4 h after completing infusion in 8/8 |
|
|
7/9 |
Ocular response to treatment; 3/7 experienced recurrent |
|
|
|
ocular disease |
|
|
2/9 |
Refractory ocular disease requiring ORT complete |
|
|
|
response |
|
|
|
7 pts with PIOL/PCNSL had complete response of |
|
|
|
CNS disease |
|
(Continued)
Lymphoma Intraocular Primary 184
Table 10.1 (Continued)
Patient Characteristics |
|
|
|
Treatment Regimen |
N |
Outcome |
Author |
|
|
|
|
17 PIOL pts |
|
OS of 39 months from diagnosis |
Hormigo, et. al.15 |
|
|
OS of 60 months from onset ocular sx |
|
Chemo |
4 |
|
|
Chemo + ORT |
8 |
|
|
Chemo + OWBRT |
2 |
|
|
ORT |
3 |
|
|
14 PIOL/PCNSL pts |
|
OS of 24 months from diagnosis |
|
|
|
OS of 35 months from onset ocular symptoms |
|
Chemo |
4 |
|
|
Chemo + OWBRT |
8 |
|
|
Chemo + WBRT |
1 |
|
|
OWBRT |
2 |
|
|
|
|
|
|
aChemo was variable and included IT-MTX as well as unstated IT and systemic chemotherapeutics. bThese patients also received either ORT or OWBRT + IT-MTX.
PIOL/PCNSL = combined ocular and cerebral disease; PIOL = exclusive ocular disease; OWBRT = ocular and whole-brain radiation therapy; ORT = ocular radiation therapy; IT = intrathecal; S = systemic; MTX = methotrexate; ARA-C = cytarabine; IV = intravenous.
PIOL of Treatment and Management
185
186 Primary Intraocular Lymphoma
are at their most susceptible to a host of opportunistic organisms.110 Clearly, AIDS PCNSL and PIOL patients present a challenge to treatment.
References
1.Jellinger K, Radaskiewicz TH, Slowik F. (1975) Primary malignant lymphomas of the central nervous system in man. Acta Neuropathol Suppl (Berl) Suppl 6: 95–102.
2.Fine HA, Mayer RJ. (1993) Primary central nervous system lymphoma. Ann Intern Med 119(11): 1093–1104.
3.Panageas KS, Elkin EB, DeAngelis LM, et al. (2005) Trends in survival from primary central nervous system lymphoma, 1975–1999: a population-based analysis. Cancer 104(11): 2466–2472.
4.DeAngelis LM, Seiferheld W, Schold SC, et al. (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol 20(24): 4643–4648.
5.Freeman C, Berg JW, Cutler SJ. (1972) Occurrence and prognosis of extranodal lymphomas. Cancer 29(1): 252–260.
6.Henry JM, Heffner RR, Jr., Dillard SH, et al. (1974) Primary malignant lymphomas of the central nervous system. Cancer 34(4): 1293–1302.
7.Schaumburg HH, Plank CR, Adams RD. (1972) The reticulum cell sarcoma — microglioma group of brain tumours. A consideration of their clinical features and therapy. Brain 95(2): 199–212.
8.Baxter JD, Harris AW. (1975) Mechanism of glucocorticoid action: general features, with reference to steroid-mediated immunosuppression. Transplant Proc 7(1): 55–65.
9.Gametchu B. (1987) Glucocorticoid receptor-like antigen in lymphoma cell membranes: correlation to cell lysis. Science 236(4800): 456–461.
10.Wyllie AH. (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284(5756): 555–556.
11.Goldin A, Sandberg JS, Henderson ES, et al. (1971) The chemotherapy of human and animal acute leukemia. Cancer Chemother Rep 55(4): 309–505.
12.Claman HN. (1972) Corticosteroids and lymphoid cells. N Engl J Med 287(8): 388–397.
13Sentman CL, Shurter JR, Hockenberry D, et al. (1991) Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 879.
14.Wallace DJ, Shen DF, Reed GF, et al. (2006) Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma. Invest Ophthalmol Vis Sci 47(7): 2750–2756.
Management and Treatment of PIOL 187
15.Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. (2004) Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 126(2): 202–208.
16.Herrlinger U, Schabet M, Bitzer M, et al. (1999) Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 43(3): 219–226.
17.Herrlinger U. (1999) Primary CNS lymphoma: findings outside the brain. J Neurooncol 43(3): 227–230.
18.Basso U, Brandes AA. (2002) Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. Eur J Cancer 38(10): 1298–1312.
19.Geppert M, Ostertag CB, Seitz G, Kiessling M. (1990) Glucocorticoid therapy obscures the diagnosis of cerebral lymphoma. Acta Neuropathol (Berl) 80(6): 629–634.
20.Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. (1993) The clinical spectrum of ocular lymphoma. Cancer 72(3): 843–849.
21.Whitcup SM, Chan CC, Buggage RR, et al. (2000) Improving the diagnostic yield of vitrectomy for intraocular lymphoma [letter; comment]. Arch Ophthalmol 118(3): 446.
22.Cox JD, Ang KK. (2003) Radiation Oncology: Rationale, Technique, Results. Mosby, St. Louis.
23.Adams RD. (1975) Certain notable clinical attributes of the histiocytic sarcomas of the central nervous system. Acta Neuropathol Suppl (Berl) Suppl 6: 177–180.
24.Freeman LN, Schachat AP, Knox DL, et al. (1987) Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma.
Ophthalmology 94: 1631–1639.
25.Char DH, Ljung BM, Deschenes J, Miller TR. (1988) Intraocular lymphoma: immunological and cytological analysis. Br J Ophthalmol 72(12): 905–911.
26.Char DH, Ljung BM, Miller T, Phillips T. (1988) Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management.
Ophthalmology 95: 625–630.
27.Char DH, Margolis L, Newman AB. (1981) Ocular reticulum cell sarcoma.
Am J Ophthalmol 91(4): 480–483.
28.Nelson DF, Martz KL, Bonner H, et al. (1992) Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23(1): 9–17.
29.Deangelis LM, Yahalom J, Rosenblum M, Posner JB. (1987) Primary CNS lymphoma: managing patients with spontaneous and AIDS-related disease.
Oncology (Williston Park) 1(6): 52–62.
188Primary Intraocular Lymphoma
30.Corry J, Smith JG, Wirth A, et al. (1998) Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41(3): 615–620.
31.Akpek EK, Ahmed I, Hochberg FH, et al. (1999) Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 106(9): 1805–1810.
32.Neuwelt EA, Goldman DL, Dahlborg SA, et al. (1991) Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9(9): 1580–1590.
33.Strauchen JA, Dalton J, Friedman AH. (1989) Chemotherapy in the management of intraocular lymphoma. Cancer 63(10): 1918–1921.
34.Levy-Clarke GA, Chan CC, Nussenblatt RB. (2005) Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am 19(4): 739–749.
35.Chabner BA, Allegra CJ, Curt GA, et al. (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76(3): 907–912.
36.Herbst KD, Corder MP, Justice GR. (1976) Successful therapy with methotrexate of a multicentric mixed lymphoma of the central nervous system. Cancer 38(4): 1476–1478.
37.Ervin T, Canellos GP. (1980) Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45(7): 1556–1557.
38.Henson JW, Yang J, Batchelor T. (1999) Intraocular methotrexate level after high-dose intravenous infusion. J Clin Oncol 17(4): 1329.
39.Batchelor TT, Kolak G, Ciordia R, et al. (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9(2): 711–715.
40.de Smet M, Vancs VS, Kohler D, et al. (1999) Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 83(4): 448–451.
41.Smith JR, Rosenbaum JT, Wilson DJ, et al. (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109(9): 1709–1716.
42.Chan CC, Wallace DJ. (2004) Intraocular lymphoma: update on diagnosis and management. Cancer Control 11(5): 285–295.
43.Rapoport SI. (1970) Effect of concentrated solutions on blood-brain barrier. Am J Physiol 219(1): 270–274.
44.Rapoport SI, Hori M, Klatzo I. (1972) Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol 223(2): 323–331.
45.Rapoport SI. (2001) Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin Investig Drugs 10(10): 1809–1818.
Management and Treatment of PIOL 189
46.Rapoport SI. (2000) Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 20(2): 217–230.
47.Rapoport SI, Hori M, Klatzo I. (1971) Reversible osmotic opening of the blood-brain barrier. Science 173(4001): 1026–1028.
48.Rapoport SI, Matthews K, Thompson HK, Pettigrew KD. (1977) Osmotic opening of the blood-brain barrier in the rhesus monkey without measurable brain edema. Brain Res 136(1): 23–29.
49.Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. (1982) Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA 79(14): 4420–4423.
50.Baehring JM, Androudi S, Longtine JJ, et al. (2005) Analysis of clonal immunoglobulin heavy chain rearrangements in ocular lymphoma. Cancer 104(3): 591–597.
51.Rockwood EJ, Zakov ZN, Bay JW. (1984) Combined malignant lymphoma of the eye and CNS (reticulum-cell sarcoma). J Neurosurg 61: 369–374.
52.Chan CC, Buggage RR, Nussenblatt RB. (2002) Intraocular lymphoma. Curr Opin Ophthalmol 13(6): 411–418.
53.Ferreri AJ, Blay JY, Reni M, et al. (2002) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13(4): 531–538.
54.O’Neill BP, O’Fallon JR, Earle JD, et al. (1995) Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 33(3): 663–673.
55.Glass J, Gruber ML, Cher L, Hochberg FH. (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81(2): 188–195.
56.Gabbai AA, Hochberg FH, Linggood RM, et al. (1989) High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J Neurosurg 70(2): 190–194.
57.Schultz C, Scott C, Sherman W, et al. (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88–06. J Clin Oncol 14(2): 556–564.
58.Abrey LE, Yahalom J, DeAngelis LM. (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18(17): 3144–3150.
59.Golay JT, Clark EA, Beverley PC. (1985) The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 135(6): 3795–3801.
190Primary Intraocular Lymphoma
60.Clark EA, Shu G. (1987) Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. J Immunol 138(3): 720–725.
61.Golay JT. (1986) Functional B-lymphocyte surface antigens. Immunology 59(1): 1–5.
62.Hultin LE, Hausner MA, Hultin PM, Giorgi JV. (1993) CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14(2): 196–204.
63.Katopodis O, Liossis SN, Viglis V, et al. (2003) Expansion of CD8+ T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma. Br J Haematol 120(3): 478–481.
64.(1994) Phase II results using a new antibody in the treatment of lymphoma.
Oncology (Williston Park) 8(12): 84, 87.
65.Anderson DR, Grillo-Lopez A, Varns C, et al. (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. Biochem Soc Trans 25(2): 705–708.
66.Takami A, Hayashi T, Kita D, et al. (2006) Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab. Cancer Sci 97(1): 80–83.
67.Pels H, Schulz H, Manzke O, et al. (2002) Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 59(3): 213–216.
68.Pels H, Deckert-Schluter M, Glasmacher A, et al. (2000) Primary central nervous system lymphoma: a clinicopathological study of 28 cases. Hematol Oncol 18(1): 21–32.
69.Dietlein M, Pels H, Schulz H, et al. (2005) Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol 74(4): 348–352.
70.Mordenti J, Thomsen K, Licko V, et al. (1999) Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci 52(1): 101–106.
71.Kim H, Csaky KG, Chan CC, et al. (2006) The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res 82(5): 760–766.
72.Velez G, de Smet MD, Whitcup SM, et al. (2000) Iris involvement in primary intraocular lymphoma: report of two cases and review of the literature. Surv Ophthalmol 44(6): 518–526.
73.Schaedel O, Reiter Y. (2006) Antibodies and their fragments as anti-cancer agents. Curr Pharm Des 12(3): 363–378.
Management and Treatment of PIOL 191
74.Kaminski MS, Zelenetz AD, Press OW, et al. (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 19(19): 3918–3928.
75.Krasner C, Joyce RM. (2001) Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin’s lymphoma. Curr Pharm Biotechnol 2(4): 341–349.
76.FitzGerald DJ, Kreitman R, Wilson W, et al. (2004) Recombinant immunotoxins for treating cancer. Int J Med Microbiol 293(7–8): 577–582.
77.Philip T, Guglielmi C, Hagenbeek A, et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333(23): 1540–1545.
78.Soussain C, Merle-Beral H, Reux I, et al. (1996) A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma 23(3–4): 339–345.
79.Soussain C, Suzan F, Hoang-Xuan K, et al. (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19(3): 742–749.
80.Chan CC. (2003) Molecular pathology of primary intraocular lymphoma.
Trans Am Ophthalmol Soc 101: 275–292.
81.Chan CC, Shen D, Hackett JJ, et al. (2003) Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology 110(2): 421–426.
82.Hendrix CW, Flexner C, MacFarland RT, et al. (2000) Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44(6): 1667–1673.
83.Wu L, LaRosa G, Kassam N, et al. (1997) Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 186(8): 1373–1381.
84.Abrey LE, DeAngelis LM, Yahalom J. (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16(3): 859–863.
85.Hoffman PM, McKelvie P, Hall AJ, et al. (2003) Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye 17(4): 513–521.
86.Kroll RA, Neuwelt EA. (1998) Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42(5): 1083–1099; discussion 1099–1100.
192Primary Intraocular Lymphoma
87.Remsen LG, McCormick CI, Sexton G, et al. (1995) Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence. Clin Cancer Res 1(7): 731–739.
88.Dahlborg SA, Henner WD, Crossen JR, et al. (1996) Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2(3): 166.
89.Frappaz D, Bouffet E, Cochat P, et al. (1988) [Hemoperfusion on charcoal and hemodialysis in acute poisoning caused by methotrexate]. Presse Med 17(23): 1209–1213.
90.Thierry FX, Vernier I, Dueymes JM, et al. (1989) Acute renal failure after high-dose methotrexate therapy. Role of hemodialysis and plasma exchange in methotrexate removal. Nephron 51(3): 416–417.
91.Flombaum CD, Meyers PA. (1999) High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 17(5): 1589–1594.
92.Makino K, Kochi M, Nakamura H, et al. (2005) Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma — case report. Neurol Med Chir (Tokyo) 45(12): 650–652.
93.Tuo J, Smith BC, Bojanowski CM, et al. (2004) The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. Faseb J 18(11): 1297–1299.
94.Klein RJ, Zeiss C, Chew EY, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308(5720): 385–389.
95.Edwards AO, Ritter R, 3rd, Abel KJ, et al. (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308(5720): 421–424.
96.Haines JL, Hauser MA, Schmidt S, et al. (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308(5720): 419–421.
97.Hageman GS, Anderson DH, Johnson LV, et al. (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102(20): 7227–7232.
98.Zareparsi S, Branham KE, Li M, et al. (2005) Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to agerelated macular degeneration. Am J Hum Genet 77(1): 149–153.
99.Conley YP, Thalamuthu A, Jakobsdottir J, et al. (2005) Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement
Management and Treatment of PIOL 193
system in the etiology of age-related maculopathy. Hum Mol Genet 14(14): 1991–2002.
100.Linnebank M, Pels H, Kleczar N, et al. (2005) MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 64(5): 912–913.
101.Seidemann K, Book M, Zimmermann M, et al. (2006) MTHFR 677 (C T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
Ann Hematol: 1–10.
102.Jahnke K, Korfel A, Martus P, et al. (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16(3): 445–449.
103.Melberg NS, Thomas MA. (1995) Nuclear sclerotic cataract after vitrectomy in patients younger than 50 years of age. Ophthalmology 102(10): 1466–1471.
104.Holekamp NM, Shui YB, Beebe DC. (2005) Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation. Am J Ophthalmol 139(2): 302–310.
105.Doolittle ND, Miner ME, Hall WA, et al. (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88(3): 637–647.
106.Pels H, Schulz H, Schlegel U, Engert A. (2003) Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 26(4): 351–354.
107.Wolf T, Brodt HR, Fichtlscherer S, et al. (2005) Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 46(2): 207–215.
108.Cheung TW. (2004) AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. “On the offensive — the Trojan Horse is being destroyed” — Part B: Malignant lymphoma. Cancer Invest 22(5): 787–798.
109.Baumgartner JE, Rachlin JR, Beckstead JH, et al. (1990) Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 73(2): 206–211.
110.Levine AM. (1992) Acquired immunodeficiency syndrome-related lymphoma. Blood 80(1): 8–20.